NCT05738538

Expanded Access to Ziftomenib

• Status: Available
• Phase: —
• Study type: Expanded Access
• Enrollment: —
• Sponsor: Kura Oncology, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: —

Summary

Requests for single patient expanded access to ziftomenib monotherapy may be considered for eligible adult patients with Acute Lymphoblastic Leukemia (ALL) with KMT2A rearrangements, or Acute Myeloid Leukemia (AML), with NPM1 mutations or KMT2A rearrangements. To request access, use Responsible Party contact information provided in this record. Expanded access for ziftomenib is only available in the United States.

Detailed description

• Subsection Condition: * NPM1 mutation in AML patients * KMT2A rearrangement in AML patients * KMT2A rearrangement in ALL patients

Conditions

• Acute Lymphoblastic Leukemia, With Appropriate Mutations
• Acute Myeloid Leukemia, With NPM1 Mutations

Interventions

Type	Name	Description
DRUG	ziftomenib

Timeline

• First posted: 2023-02-22
• Last updated: 2025-06-04